Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BLU-5937 in Healthy Volunteers
NCT03638180Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of camlipixant in chronic cough (3 arms), sponsored by GSK. Primary endpoint: Treatment Emergent Adverse Events. Started Jul 2018; status: completed.
02
Drugs
camlipixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT03638180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638180.